VistaGen Therapeutics (VTGN) investor relations material

Platform overview and clinical insights

• Developing a new class of intranasal neuroscience candidates called pherines, with fasedienol as the lead asset, targeting neural circuits via nose-to-brain delivery for rapid onset and favorable tolerability in social anxiety disorder (SAD).

• Fasedienol aims for acute treatment of SAD, showing rapid symptom reduction in both open label and controlled settings, with effects measured by the Subjective Units of Distress Scale.

• Open label data suggest real-world utility in reducing avoidance and increasing engagement, with flexible dosing up to six times daily based on individual needs.

Clinical trial updates and data analysis

• The PALISADE program includes four phase III studies; PALISADE-2 showed statistical separation, while PALISADE-1 and 3 did not, and PALISADE-4 results are expected by end of the current quarter.

• Placebo response variability has been a challenge; adjustments for PALISADE-4 include enhanced placebo mitigation, refined recruitment, and updated statistical analysis plans using AI and machine learning.

• Modifications to PALISADE-4's statistical plan were made to align with FDA guidance, focusing on covariate balancing and rigorous analysis.

Regulatory and commercialization strategy

• Ongoing discussions with the FDA will determine if the totality of data, including one positive phase III trial and safety milestones, is sufficient for NDA submission.

• Achieving ICH safety requirements by quarter-end is a key milestone, supporting advocacy for registration.

• Strategic optionality is maintained for financing, commercialization, and partnerships, with a focus on rational capital allocation.